International Journal of Andrology, 1987, **10**, pages 829–831

Author index

Abildgaard N. 203
Abildgaard U. 347
Aitken R.J. 643
Åkerlöf E. 663
Amtorp O. 347
Andjus R.K. 773
Andrews P.W. 95
Antolín M. 597
Arnold H. 311
Atlas S.A. 353

Baker H.W.G. 441
Bagger-Sjöbäck D. 359
Bagshawe K.D. 301, 389
Bajorin D. 285
Bajorunas D. 381
Bansal N. 793
Bardin C.W. 691
Barni T. 457
Bartlett J.M.S. 603, 701
Bartoov B. 685
Becker H. 1
Begent R.H.J. 301, 389
Bendvold E. 463
Berg A.Å. 647
Bergh A. 765, 785, 803
Bergmann L. 311
Bergmann M. 481
Berthelsen J.G. 19, 173, 203, 371
Bialy G. 619
Blye R.P. 619
Boiesen P. 181
Bonfanti L. 457
Bonfert B. 311
Bosl G.J. 285, 353, 381
Brada M. 247
Bruun E. 187, 199
Bujan L. 571
Bussar-Maatz R. 277
Bygdeman M. 463

Caldini A.L. 457
Carlström K. 581
Casano R. 457
Casileth B. 385
Casper J. 105, 139
Castellanos J.M. 597
Catalán R. 597
Chakravarti R.N. 793
Chan S.Y.W. 517
Chavarría M.E. 507
Chelo E. 457
Collette J. 29
Comhaire F.H. 653, 671
Cortes D. 589
Crawford S.M. 301

Damber J.E. 785, 803
Daugaard G. 319, 347
Debruyne F.M.J. 51
De Pauw M. 239
DeLozier-Blanchet C.D. 69
Dikman S. 325
Dölken G. 311

Eble J.N. 115
Einhorn L.H. 115, 399
Eliasson R. 435
Eneroth P. 463
Engel E. 69
Engström B. 359
Engström W. 79
Eriksson A. 581
Evan G. 57

Farley T.M.M. 471
Feitz W.F.J. 51
Fenderson B. 95
Fink U. 311
Fonatsch C. 105
Forti G. 457
Franchimont P. 39
Fredricsson B. 663
Freund I. 447
Fried P. 385
Friedman N.B. 43
Frimodt-Møller C. 187, 199

Galard R. 597
Ganguly N.K. 793
Geller N.L. 285
Giwercman A. 19, 173, 187, 191, 199, 209
Gottlieb C. 463
Grandjean H. 571
Grootegoed J.A. 727, 753
Gu Z.-P. 741
Gunsalus G.L. 691
Gustafsson K. 495
Gustafsson O. 663
Guttenplan J. 325

Hackeng W.H.L. 747
Hakamori S.-I. 95
Hammar M. 647

Hansen H.H. 319
Hansen S.O. 203
Hargreave T.B. 221, 393, 421
Harstrick A. 139
Hartlapp J.H. 277
Hartmann M. 1
Hecht Th. 311
Hecker H. 311
Henriksen O. 191
Henriksson P. 581
Hirsch A. 359
Ho A.D. 311
Hoffmann L. 311
Holden L. 301
Holstein A.F. 1
Holstein-Rathlou N.H. 347
Hopkins B. 79
Hrudka F. 809
Hu X.Z. 471
Huhtaniemi I. 803
Husgafvel-Pursiainen K. 431
Hustin J. 29

Illiger J. 311
Irby D.C. 625

Jackobsen G.K. 121
Jackson A.E. 625
Jauhiainen A. 489
Jayaraman S. 635
Jennings M.G. 441
Jensen H. 203
Jensen K.E. 191
Jing S.S. 471
Johansen B. 203
Johnsen Ø. 435
Jones W.G. 239

Kallajoki M. 731
Kaulen H. 311
Kaye S.B. 239
Kelly M.J. 721
Kennedy B.J. 363
Khan S.A. 495, 711
Kholkute S.D. 635
Kjær L. 191
Knuth U.A. 447
Kovačević R. 773
de Kretser D.M. 525, 625
Kroos M.J. 753
Krsmanović L. 773
Kumar R.A. 635

Läckgren G. 647
Lähdetie J. 431
Lan, J. 471
Laurell G. 359
Lehmann D. 163
Leiba S. 685
Leitner S.P. 353
Lenz S. 187, 199
Leyssac P.P. 347
Li, F.D. 471
Li G.Z. 471
Li S.Q. 517
Lindberg M.C. 619
Lindh M. 495, 711
Livni E. 685
Luna M. 507
Lundin A. 663
Lunell N.O. 663

Maddocks S. 535
Magaña P. 597
Majumdar S. 793
Malmi R. 157
Manegold C. 311
Mansat A. 571
Marić D. 773
Marlin S.A. 619
Martinéz R. 507
Mathson K. 647
Mayr A. 311
Mendis-Handagama S.M.L.C. 525
Miao Z.R. 471
Mićić S. 681
Mieusset R. 571
Moel D. 325
Morris I.D. 691
Mulder H. 747
Munck-Hansen J. 203
Musto N.A. 691
Müller Hj. 163
Müller J. 19, 147, 173, 209, 543, 589
Müller R.-P. 447

Naqvi R.H. 619
Natali A. 457
Nauadu P.L. 441
Newlands E.S. 301, 389
Nielsen E.S. 255
Niemi M. 37, 169, 417
Nieschlag E. 447
Nylund L. 663

O'Leary P.C. 625
Oliver R.T.D. 85, 263
Orlando C. 457
Østerlind A. 203
Ozols R.F. 291

Parkinson M.C. 147
Peckham M.J. 247
Pedersen K.V. 181
Pedersen M. 255
Pektasides D. 389
Peng X.S. 471
Pfreundschuh M. 311
Pizzocaro G. 269
Pöllänen P. 37
Pötter R. 447
Pontonnier F. 571
Pousette Å. 663
Preibisz J.J. 353
Preiss J. 311
Puri C.P. 635

Rabes H.M. 127
Ramaekers F.C.S. 51
Rasmussen L.H. 203
Reyes A. 507
Risbridger G.P. 525
Ritzén E.M. 495, 711
Rosenborg L. 663
Rørth M. 255, 319
Roth B.J. 115
Rustin G.J.S. 301, 389

Safirstein R. 325
Sagiv M. 685
Salonen I. 731
Samuels B.L. 363
Scheiner E. 353
Schindelmeiser J. 481
Schmoll H.-J. 105, 139, 311
Schnaidt U. 105
Schofield P. 79
Schoonjans F. 653
Schopman W. 747
Schubert I. 311
Schultz H. 255
Schütte B. 1
Schwartz S. 597
Sealey J.E. 353
Segenreich E. 685
Sehested M. 121
Serio M. 457
Servadio C. 685
Setchell B.P. 535
Sharpe R.M. 603, 701
Shohat B. 685
Sikora K. 57
Simonović I. 773
Singer R. 685
Skakkebæk N.E. 19, 147, 173, 187, 191, 199, 209, 589
Slager E. 747
Sledge G.W. 115
Sleijfer D.Th. 239
Smith J.H.F. 721
Söder O. 495
Söderström K.-O. 157
Southwick G.J. 441
Sowerbutts S.F. 535
Spaander P. 239
Stege R. 581
Steinfeld A. 385
Stenfeld R. 385
Stojilković S. 773
Stoter G. 239, 407
Sukhija N. 793
Svanborg K. 463
Syed V. 495, 711
Sylvester R. 239

Temple-Smith P.D. 441
Ten Bokkel Huinink W.W. 239
Thau R.B. 691
Thomas W.E.G. 721
Thomsen C. 191
Toebosch A.M.W. 753

Van Oosterom A.T. 239
Vanha-Perttula T. 489
Vaugnat P. 69
Vendrik C.P.J. 239
Vermeulen L. 653
Vogelzang N.J. 225, 363, 423
Von der Maase H. 173, 209, 255

Walt H. 69
Wan F. 741
Wang C. 517
Watson J. 57
Weiss J. 311
Weissbach L. 277
Wheatley R. 721
Widmark A. 785
Winston J. 325
Wong Y. 471
Wu F.C.W. 603
Wu X.Q. 471
Wuhrman B.P. 115

Ye X.M. 471
Yu Z.-H. 741

Zeng F.X. 471
Zenzes M.T. 447
Zetterlund C.G. 181
Zhang X.-D. 741
Zhong Z.-Z. 471
Zhou R.H. 619
Zukerman Z. 685

Adenosine
Advanced
AFP
poor pro
producti
105
Aldosteron
che
Alkaline p
cell
Androgen
concentr
701
concentr
epi
levels af
691
monitori
Androgen
209
Androgens
pro
Aneuploid
Antisperm
Autoimmu
Azoosperr
incidenc
681
seminal

Bilateral t
age at d
histolog
time lag
Biopsy, te
complic
screenin
Birth defe
Bleomycin
Blood–tes
fow
Bone met
can
Brain met
Bromocrip
rats

Calcitonin
Calmodul
507
Carbohyd
Carcinom

International Journal of Andrology, 1987, **10**, pages 833–837

Subject index

Adenosine triphosphate in human semen 653
Advanced disease, treatment 311
AFP
  poor prognosis patients 225
  production in testicular tumour cell lines 105
Aldosterone levels in patients treated with chemotherapy 353
Alkaline phosphatase, embryonal carcinoma cells 95
Androgen binding protein
  concentrations in serum and testicular fluid 701
  concentrations in serum, testis and epididymis 691
  levels after impairment of spermatogenesis 691, 701
  monitoring of Sertoli cell function 701
Androgen insensitivity syndrome, CIS 176, 209
Androgens, adrenal after treatment for prostatic cancer 581
Aneuploidy, testicular cancer 57
Antisperm antibodies, CIS 163
Autoimmunity, testicular cancer 163
Azoospermia
  incidence of aetiological obstructive factors 681
  seminal somatomedin C 447

Bilateral testicular cancer
  age at diagnosis 203
  histology 203
  time lag between tumours 203
Biopsy, testicular
  complications 199
  screening for CIS 199, 173
Birth defects after radiation therapy 385
Bleomycin, lung toxicity 311
Blood–testis barrier, formation of, in domestic fowl 481
Bone metastases in patients with testicular cancer 225
Brain metastases, treatment 301
Bromocriptine, effect of chronic treatment of rats 773

Calcitonin, testosterone effect on 747
Calmodulin, effect on human sperm motility 507
Carbohydrate antigens, SSEA-3, SSEA-4 95
Carcinoma-in-situ *see* CIS

Cell growth, oncogenetic control 57
Cell lines
  testicular cancer 95, 105, 139
    hormone production 105
Chemotherapy
  and CIS 209
  and fertility 391
Chromosomal changes
  and radio- and chemotherapy 391
  testicular cancer cells 69, 105
Cigarette smoking, genotoxic hazard to male germ cells 431
CIS cells
  androgen insensitivity syndrome 173
  antisperm antibodies 163
  chemotherapy 209
  contralateral testis, incidence of 173
  detected by magnetic resonance imaging 173, 191
  detected by ultrasound 173, 187
  glycoconjugates 157
  glycogen 19
  glycoproteins 163
  gonadal dysgenesis 173
  gonadoblastoma 19
  IgG 163
  in infantile testis 543
  incidence 173, 181, 209
  infertility 173
  invasive cancer 19
  irradiation therapy 209
  lectin binding 157, 163
  morphology
    in relation to gonocytes 19
    in relation to seminoma cells 19
  orchidectomy 95
  risk groups in infancy 543
  screening 173, 199
  somatosexual ambiguity 173
  spontaneous course 209
  staining for PlAP 19, 29
  testicular feminization syndrome 291
  undescended testis 173, 181
Cisplatin
  and ifosfamide salvage therapy 399
  and vinblastine salvage therapy 399
  and VP-16 salvage therapy 399
  antitumour activity in xenografts 29
  cardiovascular toxicity 353
  effect on glomerular filtration rate 325, 347
  effect on LH, FSH and testosterone 381
  effect on serum phosphorus 353
  haemodynamic effect 325, 347

high dose regimens 291, 311, 319
hypomagnesaemia induction 325, 353
mechanism of cytotoxicity 325
nephrotoxicity 325, 347
nephrotoxicity effect of frusemide 325
nephrotoxicity effect of hypertonic solutions 325
ototoxicity 359
polyruria induction 325, 347
renal excretion 325
renal metabolism 325
renal uptake 325
toxicity of high dose 311
Cisplatin analogue, antitumour activity in xenografts 139
Concanavalin A 157
binding to CIS cells 157, 163
Conception rates, before and after antineoplastic treatment 371
Contralateral testicle, incidence of testicular cancer 203
Cryopreservation of semen in patients with testicular cancer 371
Cryptorchid testis, staining for PlAP 29
Cryptorchidism
carcinoma-in-situ detected by ultrasound 187
incidence of CIS 173, 181
rat, morphological changes 803
rat, steroids and gonadotrophin receptor levels 803
Cytochrome C oxidase, demonstration in spermatozoa 809
Cytogenetics, testicular cancer 69
Cytokeratin
normal testicular tissue 51
testicular cancer tissue 51, 95

Densitometry, in infantile testis 543
Desmin, testicular tissue 51
DNA content
advanced germ cell tumours, prognostic value 115
spermatocytic seminoma cells 147

Embryonal carcinoma
biochemical cell properties 95
cell lines
human 95
murine 95
differentiation of cells in culture 95
Embryonal germ cells, morphology 1
Epididymis, proteins in epididymal fluid 441
Ethane demethane sulphonate, effect on rat seminiferous tubule function 625
Extragonadal germ cell tumours, proposed aetiology 43

Familial occurrence, testicular cancer 85
Feminization, testicular and CIS 173, 209
Fertility
after chemotherapy for testicular cancer 371, 389
after lymphadenectomy for testicular cancer 371
after radiotherapy for testicular cancer 371
before testicular cancer 371
effect of testicular hyperthermia 571
marmoset, effect of continuous light environment 635
prostaglandins in seminal fluid 463
semen assessment 653
Fetal germ cells, morphology 1
Fibronectin, embryonal carcinoma cells 95
Flow cytometry, DNA content in testicular cancer 115
FSH
in rats after injection of EDS 625
patients treated with chemotherapy 381
plasma levels in normal and vasectomized males 471

Genetic implications, radio- and chemotherapy 371, 385
Germ cells
adult, staining for PlAP 29
effect of cigarette smoking 431
embryonal, staining for PlAP 29
fetal, staining for PlAP 29
glycoconjugates 157
human, abnormal infantile 543
infantile, staining for PlAP 29
lectin-binding sites 157
morphological characterization 1
normal ultrastructure 1
primordial 43
Glycoconjugates
CIS cells 157
germ cells 157
seminoma cells 157
Glycogen
CIS cells 19
germ cells 1, 19
Glycolipids, embryonal carcinoma cells 95
Glycoproteins, CIS cells 163
Glycosyltransferase, embryonal carcinoma cells 95
Gonadal dysgenesis and CIS 173
Gonadotrophins
development of testicular cancer 19
levels, patients treated with chemotherapy 381
Gonocyte morphology in relation to CIS cells 19
Gonocytoma (*see also* Seminoma) 19
Gonocytoma-in-situ (*see also* CIS) 19
Gossypol enantiomers, antifertility effect in male hamsters 619
Growth factors, in rat testis 495
Growth regulatory genes, malignant testicular tumour cells 79

Hamster egg penetration test 517
hCG
poor prognosis patients 225
production, testicular tumour cells lines 105

treatment, human undescended prepubertal testis 647
High dose chemotherapy 291, 311, 319
HLA antigens
familial germ cell tumour 85
normal testicular tissue 37
testicular cancer 85
HMG-CoA reductase gene, testicular cancer 79
HPA 157
Hyperthermia, effect on human spermatogenesis 571
Hyperprolactinaemia
effect on androgenic responsiveness in rat testis 773
effect on Leydig cell numbers in rats 773
Hypogonadism after chemotherapy 381
Hypomagnesaemia patients treated with cisplatin 325, 353

Ifosfamide salvage therapy 399
IGF II gene, testicular cancer 79
IgG, CIS cells 163
Immunological environment, normal testis 37
Incidence
bilateral testicular cancer 203
CIS 173, 181, 209
Infertility
and CIS 173
empirical method for assessment of 671
salivary testosterone levels 597
treatment with tamoxifen, effect on calcitonin secretion 747
Insulin gene, testicular cancer 79
Interferon, effect on embryonal carcinoma cells in culture 95
Interleukin-1, production in the rat testis 495
Intermediate filament protein
normal testicular tissue 51
testicular cancer 51
Irradiation therapy of CIS 209
Isochromosome 12p, testicular cancer 69

LDH, poor prognosis patients 225
LDL-receptor gene, testicular cancer 79
Lectin-binding sites in normal and malignant germ cells 157
Leydig cell
function after irradiation of the testis 209
rat, culture of 603
rat, effect of hCG treatment 765
rat, morphometric analysis of 525
rat, testosterone secretion enhancement 603
LH
in rats after EDS injection 625
inhibiting factor on Leydig cells in rats 711
patients treated with chemotherapy 381
plasma levels in normal and vasectomized males 471
Liver metastases, patients with testicular cancer 225
LRH-agonist, effect on rat testicular vasomotion 785
LSA 157
Lung metastases, patients and testicular cancer 225
Lymphadenectomy, stage IIA and IIB nonseminoma 269
Lymphocytes, normal teticular tissue 37

Macrophages, normal testicular tissue 37
Magnetic resonance imaging
CIS 173, 191
normal testis 191
Maldescent, incidence of CIS 173, 181
MHC antigens, embryonal carcinoma 95
Morphology
CIS cells 1, 19
germ cells 1, 19
gonocytes 19
nonseminoma cells 1, 19
normal testicular tissue 1
seminoma cells 1, 19
Morphometry, rat testis interstitium 525
Multivariate analysis 225, 239

Nephrotoxicity, cisplatin-based chemotherapy 325, 347, 353
Nonseminoma
lymphadenectomy in stage IIA and IIB 269
prognostic variables 239, 301
proliferation pattern 127
proliferation rate 127
relapse rate, stage I 247
stage II prognosis 277
staging 407
surveillance stage I 255
treatment of poor prognosis patients 291, 311, 319
treatment stage I 407
treatment stage II 277, 407
Nude mice, testicular cancer cells 105

Oestrogen, tumour marker 105
Oestrogens, treatment in prostatic cancer 581
Oncogenes
c-myc 57
testicular cancer 57, 69
Oncoprotein level in relation to prognosis of testicular cancer 57
normal testicular tissue 57
p62-c-myc 57
testicular cancer 57
Ototoxicity induced by cisplatin 359

Pituitary–testicular axis, testicular cancer patients 381
Placental alkaline phosphatase *see* PlAP
Placental-like alkaline phosphatase *see* PlAP
PlAP
CIS cells 19, 29
cryptorchid testis 29
developing testis 29
immunohistochemical demonstration 19, 29
normal testicular tissue 29

serum concentration in seminoma patients 263
testicular cancer cells 29
Ploidy status, testicular cancer 57, 69, 115
PNA 157
Poor prognosis
identification of patients 225
treatment 291, 301, 319
Pregnancy, estimation of likehood in infertile couples 671
Pregnenolone metabolism in human undescended prepubertal testis 647
Progesterone metabolism in human undescended prepubertal testis 647
Prognosis and oncoprotein level 57
Prognostic factors
disseminated testicular cancer 225, 239, 319
stage I testicular cancer 247
Prognostic variables, testicular cancer patients 285
Prolactin, plasma levels in normal and vasectomized males 471
Proliferation rate, testicular cancer 127
Prostaglandins in seminal fluid 463
Prostatic cancer, treatment effects on adrenal androgens 581

Radiation treatment, effect on offspring 385
Radiotherapy
and fertility 371
stage I nonseminoma 255
testicular function after 447
RCA I 157
Relapse rate
stage I nonseminoma 247
stage I seminoma 247
Renin levels in patients treated with cisplatin-based chemotherapy 353
Risk group, for CIS 173, 181, 209
Risk group assignment, patients with testicular cancer 285

SBA 157
Screening for CIS
methods 173
testicular biopsy 199
Semen quality
in male infected with malaria 685
after application of sperm separation techniques 663
after radiotherapy for seminoma 447
Semen
bovine, glycosidase levels 489
human, assessment by sperm characteristics and ATP concentration 653
human, effect of cigarette smoking 431
zinc in 435
Seminiferous tubule
rat, effect of EDS injection 625
rat, co-culture with Leydig cells 603
Seminoma
oncoproteins 363
proliferation pattern 127
relapse rate state I 247
staging 407
surveillance of stage I patients 263
syncytiotrophoblast-like cells 121
testicular function after orchidectomy 447
treatment 407
Seminoma cells
glycoconjugates 157
lectin binding 157
morphology in relation to CIS cells 19
Seminoma, spermatocytic
histology of adjacent tissue 147
nuclear DNA distribution 147
pathogeneis 147
Sertoli cell function 727
Sertoli cells
human, proliferation of during childhood 589
rat, assessment by ABP levels 701
rat, secretion of LH inhibitor 711
rat, transport of transferrin bound iron 753
Somatomedin C in seminal plasma 447
Somatosexual ambiguity and CIS 173
Sperm acrosin, monoclonal antibody against 731
Sperm
energetic metabolism assessed by demonstration of cytochrome C oxidase 809
human, effect of calmodulin on motility 507
human, hamster egg penetration after TEST-egg yolk buffer storage 517
human, penetration into zona-free hamster eggs 731
human, prediction of penetration rate 517
human, separation techniques 663
Sperm separation techniques 643
Spermatids, rat, transport of transferrin bound iron 753
Spermatocytic seminoma *see* Seminoma, spermatocytic 19
Spermatocytoma *see* seminoma, spermatocytic 19
Spermatogenesis
after treatment for malaria 685
human, after hyperthermia 571
impairment, effect on ABP secretion 691, 701
marmoset, effect of continuous light environment 635
patients with testicular cancer 371
Spermicides, evaluation of new agents 741
Staging, testicular cancer 407
Stereology
Sertoli cell proliferation assessment 589
in infantile testis 543
Steroid hormones
development of testicular cancer 19
production in testicular cancer cell lines 105
Steroidogenic function in human prepubertal undescended testis 647
Surgery, stage IIA and IIB nonseminoma 269

Surveillance, stage I testicular cancer 247, 263
Syncytiotrophoblast-like cells, ultrastructure 121

Teratoma oncoprotein 57
Testicular function, after seminoma 447
Testis
  human, undescended, influence of hCG treatment 647
  rat, immature, cryptorchid 803
  rat, ischaemic changes after spermatic cord clamping 721
  rat, Leydig cell response to hCG treatment 765
  rat, LH receptors 535
  rat, morphometric analysis 525
  rat, origin of testosterone production inhibitor 711
  rat, vascular response to hCG 535
Testosterone
  effect on calcitonin secretion 747
  levels after EDS injection in rats 625
  levels in patients treated with chemotherapy 381
  marmoset, effect of continuous light environment 635
  plasma levels in normal and vasectomized males 471
  salivary levels in infertility 597
Tumour markers
  poor risk patients 285
  production in testicular cancer cell lines 105

UEA I 157
Ultrasound detection of CIS 187, 209
Undescended testis, incidence of CIS 181

Vasectomy, development of autoimmune response 793
Vascular toxicity induced by combination chemotherapy 363
Vimentin
  normal testicular tissue 51
  testicular cancer tissue 51
VP-16
  high dose in bulky disease patient 311, 319
  high dose toxicity 311, 319
  salvage therapy 399

WGA 157

Xenografts, testicular cancer 139

Zinc, in human seminal plasma 435